DOsimetry and Radiation Induced NAusea in Head and Neck Cancers
Prospective Multicenter Cohort Study for the Analysis of Correlation Between Dosimetric Parameters and RANV (Radiation Associated Nausea and Vomiting) in Patients With Head and Neck Cancer Undergoing Exclusive Radiotherapy (RT)
European Institute of Oncology
180 participants
Nov 15, 2021
OBSERVATIONAL
Conditions
Summary
This is a prospective cohort study for the analysis of correlation between dosimetric parameters and RANV (Radiation Associated Nausea and Vomiting) in patients with head and neck cancer undergoing exclusive radiotherapy (RT). The primary purpose of this study is to search for a potential correlation between dosimetry and physician- and patient-rated symptoms in patients treated with exclusive radiotherapy for head and neck cancer.
Eligibility
Inclusion Criteria8
- Patients aged ≥ 18 years
- Diagnosis of primary head and neck neoplasm in the following subsites: oropharynx, nasopharynx, oral cavity, paranasal sinuses, salivary glands, and neoplasms with an unknown primary focus.
- Curative radiotherapeutic treatment with photons or protons using 3D conformal or Intensity Modulated Radiation Therapy (IMRT), Volumetric Modulated Arc Therapy (VMAT), Tomotherapy; both photon and proton treatments are allowed.
- Ability to prospectively collect and anonymously submit clinical data related to the patient, pathology, and treatment characteristics (including the radiotherapy treatment plan in RT.dose format) to a single referring center.
- Ability to prospectively collect and anonymously submit DICOM (Digital Imaging and COmmunication in Medicine) files related to pre-RT magnetic resonance imaging (MRI) to a single referring center.
- Ability to collect acute toxicity data (mucositis, xerostomia, nausea, vomiting, weight loss) during radiotherapy and at three months post-treatment.
- Ability to undergo a clinical follow-up examination three months after the completion of radiotherapy.
- Willingness to provide written informed consent for the anonymous use of data for research purposes.
Exclusion Criteria6
- Patients undergoing chemotherapy treatment (neoadjuvant or concurrent with radiotherapy).
- Patients with local and/or locoregional recurrence of head and neck disease.
- Patients previously treated with oncologic interventions in the head and neck region.
- Patients with synchronous distant metastases at the time of diagnosis.
- Inability to comprehensively collect baseline data related to the patient, pathology, and treatment characteristics (including the treatment plan) and follow-up data.
- Inability to obtain written informed consent for the anonymous use of data for research purposes.
Interventions
Curative radiotherapy treatment using 3D conformal or Intensity Modulated Radiation Therapy (IMRT) techniques.
Locations(14)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06341985